• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·CHEMFAB.NS
Share

Chemfab Alkalis Limited Stocks

₹ 367.8Last Updated 23.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 55.75M

₹ 367.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1985 and headquartered in Chennai, India, Chemfab Alkalis Limited is an international manufacturer and vendor of inorganic chemical products. The company's business activities are structured around two main segments: Chemicals and Related Products/Services, and PVC-O Pipes. Its comprehensive product range includes various chemicals like caustic soda (available in lye and flake forms), liquid chlorine, hydrogen gas, hydrochloric acid, and sodium hypochlorite/bleach liquor, in addition to industrial-grade and edible salt varieties. Formerly operating as Teamec Chlorates Limited, the company officially adopted its current name, Chemfab Alkalis Limited, in July 2017.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 08:00

AI Spending Threatens the Creditworthiness of Amazon, Meta, and Alphabet — Moody’s

25.07.2026 06:24

In July, four out of five of the short seller's bets from *The Short Game* paid off. Which ones?

25.07.2026 05:59

Nvidia and Palantir Urged the U.S. Not to Restrict "Open" AI Models Following China's Breakthrough

25.07.2026 05:03

SpaceX has successfully tested the Starship rocket for the first time since its IPO

25.07.2026 04:30

Paramount has put its merger with Warner Bros. on hold for nearly a year

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026